Share

Endocrine Society Urges Policy Makers to Follow Science on Transgender Health

Texas custody case prompts unfounded claims. A custody case in Texas has sparked heated debate and embroiled state policy makers in public discussions about the diagnosis and appropriate medical treatment of transgender children. Unfortunately, many of the claims being made about gender-affirming care for transgender and gender-incongruent individuals are inaccurate. Policies concerning the diagnosis and...
Share

In Living Color: Extending Your Practice’s Reach Via Telehealth

The advent of smart phones has enabled patients to avoid lengthy travel and made languishing in waiting rooms a thing of the past as telehealth has become more and more common in endocrinology practices. Telehealth can help manage the kind of chronic conditions, such as hypothyroidism or diabetes, that are considered hallmarks of endocrinology. Such...
Share

Targeting Patients with Pellets: A Look at Biodentical Hormones

Promoted to treat vague symptoms and conditions like “hormone imbalance,” custom-compounded bioidentical hormones are increasing in popularity — and problems. By the time the patient came into the care of endocrinologist Margaret Wierman, MD, she had already had her ovaries removed. She had presented to the obstetrics and gynecology department with very high testosterone levels...
Share

FDA Approves First Ready-to-Use Stable Liquid Glucagon for Severe Hypoglycemia

The U.S. Food and Drug Administration (FDA) recently approved a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Xeris Pharmaceuticals is marketing this new glucagon injection as GVOKE. GVOKE is the first glucagon product approved that can be administered via...
Share

Takeda Announces NATPARA Special Use Program in the U.S.

In the wake of the recall of hypoparathyroidism drug NATPARA, the drug’s manufacturer, Takeda, is working with the FDA to develop a Special Use Program. The program is intended to support patients previously prescribed NATPARA who are facing life-threatening complications as a result of discontinuation of NATPARA. Through this program, healthcare providers will be able...
Share

In the House: How Inpatient Diabetes Teams Can Improve Patient Outcomes and Reduce Costs

Becoming more common in academic institutions, diabetes management teams can play an important role in community hospitals by reducing lengths of stay and readmissions. Evidence continues to mount that focusing on patients’ diabetes through inpatient management services when they are in the hospital for other conditions pays dividends in lowering re-admissions and short-term mortality —...
Share

FDA Approves First Treatment for Severe Hypoglycemia That Can Be Administered without an Injection

BAQSIMI Product Photo - Final In July, the U.S. Food and Drug Administration approved a nasal powder glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection. Eli Lilly and Company is marketing the drug as Baqsimi. The therapy has been approved to treat severe hypoglycemia in patients with diabetes ages four and older....